GlassScriptPhysician profile
Ralph L Abraham
NPI 1013962620
$2,565.81
in general payments reported to CMS, 2019-2025
27 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $683 · 2022: $345 · 2023: $872 · 2024: $238 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,397 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,396.64 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $793.51 | 2021-2025 | Qulipta, Vraylar, Ubrelvy |
| Amgen INC. | $237.34 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $141.50 | 2020-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $140.99 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Teva Pharmaceuticals USA, INC. | $137.08 | 2020-2023 | Ajovy |
| Novo Nordisk INC | $132.79 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $113.54 | 2021-2025 | Nexletol |
| Otsuka America Pharmaceutical, INC. | $103.82 | 2022-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $88.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $78.99 | 2020-2023 | Trelegy Ellipta |
| Pfizer INC. | $78.21 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $77.50 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $66.25 | 2021 | |
| Corium, LLC | $45.47 | 2023 | Azstarys |
| Axsome Therapeutics, INC. | $45.36 | 2022-2023 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $38.32 | 2023 | |
| Antares Pharma, INC. | $35.47 | 2022-2025 | Xyosted |
| Exact Sciences Corporation | $33.83 | 2023 | Cologuard Collection Kit |
| Corcept Therapeutics | $25.27 | 2024 | Korlym |
| Allergan, INC. | $24.09 | 2020 | |
| Evoke Pharma, INC. | $23.71 | 2024 | |
| Biogen, INC. | $21.52 | 2025 | Skyclarys |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.78 | 2025 | Relistor |
| Kowa Pharmaceuticals America, INC. | $17.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.17 | 2023 | |
| Merck Sharp & Dohme LLC | $14.68 | 2025 | M-M-R II, Capvaxive, Gardasil 9 |
| Paratek Pharmaceuticals, INC. | $14.08 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.